It has been approved for the treatment of B-CLL (as third-line therapy or as second-line therapy in case of 17p deletion or TP53 mutation), where it has been shown to induce a rapid apoptosis of CLL cells, known to be BCL-2 dependent [218]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.